Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Repurchased
Growth Metrics
Income Statement
Others
Ratios

Ligand Pharmaceuticals (LGNDZ) Cash from Operations (2016 - 2025)

Ligand Pharmaceuticals (LGNDZ) has disclosed Cash from Operations for 16 consecutive years, with 45915000.0 as the latest value for Q4 2025.

  • Quarterly Cash from Operations rose 61.27% to 45915000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 49359000.0 through Dec 2025, down 49.14% year-over-year, with the annual reading at 49359000.0 for FY2025, 49.14% down from the prior year.
  • Cash from Operations hit 45915000.0 in Q4 2025 for Ligand Pharmaceuticals, up from 13090000.0 in the prior quarter.
  • In the past five years, Cash from Operations ranged from a high of 53472000.0 in Q4 2022 to a low of 25445000.0 in Q1 2025.
  • Historically, Cash from Operations has averaged 20631550.0 across 5 years, with a median of 19378500.0 in 2021.
  • Biggest five-year swings in Cash from Operations: soared 16336.59% in 2024 and later crashed 235.84% in 2025.
  • Year by year, Cash from Operations stood at 27642000.0 in 2021, then skyrocketed by 93.44% to 53472000.0 in 2022, then tumbled by 84.92% to 8065000.0 in 2023, then surged by 253.02% to 28471000.0 in 2024, then skyrocketed by 61.27% to 45915000.0 in 2025.
  • Business Quant data shows Cash from Operations for LGNDZ at 45915000.0 in Q4 2025, 13090000.0 in Q3 2025, and 15799000.0 in Q2 2025.